2型糖尿病的降糖治疗、血糖控制水平与骨折风险:巢式病例对照研究
结果显示,当前使用二甲双胍且HbA1c<7.0%或7.0-8.0%者骨折风险降低,而使用二甲双胍联合其他降糖药或胰岛素者血糖控制水平与骨折风险无关。
要点
- 二甲双胍单药且HbA1c<7.0%或7.0-8.0%者骨折风险低于未治疗者。
- 二甲双胍联合1或2种其他降糖药或使用胰岛素者,血糖控制与骨折风险无关。
- 新诊断T2DM患者降糖方案类型影响血糖控制与骨折风险的关联。
核心结论
- 当前使用二甲双胍单药且血糖控制良好或中等者,骨折风险低于未治疗患者。
- 使用二甲双胍联合其他降糖药或胰岛素者,血糖控制水平与骨折风险无关。
研究设计与样本
- 巢式病例对照研究,基于临床实践研究数据链。
- 基础人群为1995至2017年新诊断2型糖尿病患者。
- 病例为T2DM诊断后发生低创伤骨折的患者,每个病例匹配4例对照。
- 采用条件逻辑回归分析,调整多个混杂因素。
主要发现
- 当前使用二甲双胍且HbA1c<7.0%者,与未治疗者相比骨折风险降低(调整OR 0.89;95%CI 0.83-0.96)。
- 当前使用二甲双胍且HbA1c 7.0-8.0%者,与未治疗者相比骨折风险降低(调整OR 0.81;95%CI 0.73-0.90)。
- 使用二甲双胍联合1或2种其他降糖药,或使用胰岛素(单用或联合其他降糖药)者,血糖控制水平与骨折风险无显著关联。
临床怎么用
- 对新诊断T2DM患者,二甲双胍单药且HbA1c控制在<7.0%或7.0-8.0%可能降低骨折风险。
- 使用二甲双胍联合治疗或胰岛素时,血糖控制水平不能单独用于评估骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of low-trauma fractures. However, the effect of antidiabetic medication in relation to glycemic control on the risk of fracture is poorly understood. OBJECTIVE: This work aimed to evaluate the association between the level of glycemic control, use of antidiabetic medication, and risk of low-trauma fractures in patients with newly diagnosed T2DM. METHODS: We conducted a nested case-control analysis among individuals registered in the Clinical Practice Research Datalink. The base population consisted of patients with newly diagnosed T2DM from 1995 to 2017. Cases were patients with a low-trauma fracture after T2DM diagnosis. We matched 4 controls to each case. Exposures of interest were glycemic control (last glycated hemoglobin [HbA1c] level before fracture) and type of diabetes treatment. We conducted conditional logistic regression analyses adjusted for several confounders. RESULTS: We identified 8809 cases and 35 219 controls. Patients with current metformin use and HbA1c levels of less than 7.0% and between 7.0-8.0% had a reduced risk of fractures (adjusted odds ratio 0.89; 95% CI, 0.83-0.96 and 0.81; 95% CI, 0.73-0.90, respectively) compared with untreated patients. However, in patients receiving metformin plus 1 or 2 other antidiabetic drugs, or insulin (alone or in addition to other antidiabetic medication), the level of glycemic control was not associated with the risk of fracture compared with untreated patients. CONCLUSIONS: While patients with good or medium glycemic control receiving current metformin monotherapy had a lower risk of fracture compared with untreated patients, glycemic control in patients receiving treatment other than metformin was not associated with risk of fracture.
引用
- Charlier S, Vavanikunnel J, Becker C, et al. Antidiabetic Treatment, Level of Glycemic Control, and Risk of Fracture in Type 2 Diabetes: a Nested, Case-Control Study. J Clin Endocrinol Metab. 2021. PMID: 33141149. doi:10.1210/clinem/dgaa796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。